Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative MPNs
NCT07626021Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Jul 2026
- Primary completion
- Aug 2026
01
Overview
Phase 2, open-label, single-arm trial of selinexor in Myeloproliferative Neoplasm (MPN), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoint: Proportion of Participants Achieving Disease-Relevant Peripheral Blood Count Control at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07626021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626021.